Defeat Duchenne Canada is pleased to share an announcement regarding Satellos Bioscience, a Canadian clinical-stage biotechnology company developing novel therapies to treat degenerative muscle diseases. Today the company has announced that it has received FDA Fast Track Designation for SAT-3247 for the treatment of Duchenne muscular dystrophy. Satellos has clinical trial sites around the globe, including Ottawa, Canada.
The Fast Track designation is structured to expedite the development and review of new drugs to treat serious or life-threatening conditions and fill unmet medical needs.
“Fast Track designation represents an important validation of SAT-3247 and our commitment to transforming the treatment landscape for Duchenne. We believe SAT-3247’s unique regenerative mechanism has the potential to address a fundamental aspect of disease progression by re-establishing the biological signals needed for effective muscle repair and regeneration.”
Frank Gleeson, Co-Founder and CEO of Satellos Bioscience
Read the full press release below for more information.
Want to know more about Duchenne Research?
Scientists and medical experts have been tirelessly pursuing diverse approaches to defeat Duchenne muscular dystrophy. From tackling the root cause to alleviating symptoms, the field of research is vast and promising. Explore the various strategies being developed and tested, and gain insights into the future of muscular dystrophy treatment: